title: Optimizing meso-tetra-hydroxyphenyl-chlorin-mediated photodynamic therapy for basal cell carcinoma.
abstract: Meso-tetra-hydroxyphenyl-chlorin (mTHPC)-mediated photodynamic therapy (PDT) has shown to be effective in the treatment of patients with multiple basal cell carcinoma (BCC). In the present study we further optimized the drug-light interval and examined the correlation between plasma drug levels and treatment efficacy. Thirteen patients with multiple BCC (a total of 366 lesions) were included in the study. Following intravenous administration of 0.1 mg kg(-1) mTHPC, lesions were illuminated with 10 J cm(-2) light (652 nm, 100 mW cm(-2)) at 12, 24, 48, 72 or 96 h. Plasma samples were taken prior to each illumination for determination of mTHPC levels, and tumor response was evaluated at 6 months and 1 year. Both univariable and multivariable analyses showed that optimal treatment outcome was obtained for a drug-light interval of 24 h when plasma drug levels were high. Overall, good cosmetic results with little or no scarring were obtained in 87% of the treated lesions and no serious side effects were observed. We optimized mTHPC-mediated PDT for patients suffering from multiple BCC by determining the most effective drug-light interval and showed that this treatment offers significant advantages over surgical resection.
authors.affiliation: Division of Experimental Therapy (H6), The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
authors.forename: Martijn
authors.initials: M
authors.lastname: Triesscheijn
authors.forename: Marjan
authors.initials: M
authors.lastname: Ruevekamp
authors.forename: Ninja
authors.initials: N
authors.lastname: Antonini
authors.forename: Herman
authors.initials: H
authors.lastname: Neering
authors.forename: Fiona A
authors.initials: FA
authors.lastname: Stewart
authors.forename: Paul
authors.initials: P
authors.lastname: Baas
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007275:Injections, Intravenous; D008652:Mesoporphyrins / Q000627:therapeutic use*; D010778:Photochemotherapy; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D008652:Mesoporphyrins; C072269:temoporfin